Twist Bioscience Corp. Files Definitive Proxy Statement

TL;DR

<b>Twist Bioscience Corp. has filed its Definitive Proxy Statement for the period ending February 6, 2024.</b>

AI Summary

Twist Bioscience Corp (TWST) filed a Proxy Statement (DEF 14A) with the SEC on January 5, 2024. Twist Bioscience Corp. filed a Definitive Proxy Statement (DEF 14A) on January 5, 2024. The filing covers the period ending February 6, 2024. The company's fiscal year ends on September 30. Twist Bioscience Corp. is incorporated in Delaware. The company's principal business address is 681 Gateway Blvd., South San Francisco, CA 94080.

Why It Matters

For investors and stakeholders tracking Twist Bioscience Corp, this filing contains several important signals. This filing is a routine requirement for publicly traded companies to provide shareholders with information regarding upcoming meetings and voting matters. Shareholders will be informed about executive compensation, director elections, and other corporate governance issues.

Risk Assessment

Risk Level: low — Twist Bioscience Corp shows low risk based on this filing. The filing is a standard DEF 14A, indicating routine corporate governance disclosures rather than significant financial or operational changes.

Analyst Insight

Review the proxy statement for details on executive compensation, director nominations, and any shareholder proposals to understand potential impacts on corporate strategy and governance.

Key Numbers

• 2024-01-05 — Filing Date (DEF 14A)
• 2024-02-06 — Period of Report (DEF 14A)
• 0930 — Fiscal Year End (Company Data)

Key Players & Entities

• Twist Bioscience Corp. (company) — Filer
• DEF 14A (filing) — Form Type
• 2024-01-05 (date) — Filing Date
• 2024-02-06 (date) — Period of Report
• 0001581280 (company) — Central Index Key
• DE (jurisdiction) — State of Incorporation
• 0930 (fiscal_year) — Fiscal Year End
• 681 Gateway Blvd. (address) — Business Address

Forward-Looking Statements

• Twist Bioscience will continue to use equity-based compensation as a significant component of executive pay. (Twist Bioscience Corp.) — high confidence, target: 2025-09-30

FAQ

Industry Context

Twist Bioscience Corp. operates in the biotechnology sector, focusing on synthetic biology.

Regulatory Implications

As a publicly traded company, Twist Bioscience Corp. is subject to SEC regulations, including the requirement to file proxy statements.

What Investors Should Do

1. Review the executive compensation details for key management personnel.
2. Examine the proposals to be voted on by shareholders.
3. Assess the director nominees and their qualifications.

Key Dates

• 2024-01-05: Filing Date — Filing of Definitive Proxy Statement
• 2024-02-06: Period of Report End Date — Definitive Proxy Statement coverage

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard disclosure document for public companies and does not represent a change from previous filings of the same type.

Filing Documents

• twst-20240104.htm (DEF 14A) — 1359KB
• twst-20240104_g1.jpg (GRAPHIC) — 10KB
• twst-20240104_g10.jpg (GRAPHIC) — 2364KB
• twst-20240104_g2.jpg (GRAPHIC) — 1KB
• twst-20240104_g3.jpg (GRAPHIC) — 52KB
• twst-20240104_g4.jpg (GRAPHIC) — 54KB
• twst-20240104_g5.jpg (GRAPHIC) — 27KB
• twst-20240104_g6.jpg (GRAPHIC) — 377KB
• twst-20240104_g7.jpg (GRAPHIC) — 292KB
• twst-20240104_g8.jpg (GRAPHIC) — 272KB
• twst-20240104_g9.jpg (GRAPHIC) — 2213KB
• 0001628280-24-000650.txt (&nbsp;) — 14129KB
• twst-20240104.xsd (EX-101.SCH) — 4KB
• twst-20240104_def.xml (EX-101.DEF) — 6KB
• twst-20240104_lab.xml (EX-101.LAB) — 9KB
• twst-20240104_pre.xml (EX-101.PRE) — 5KB
• twst-20240104_htm.xml (XML) — 124KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 21 Compensation Discussion and Analysis 21 Compensation Committee Interlocks and Insider Participation 40 Summary Compensation Table 41 Grants of Plan-Based Awards in Fiscal 202 3 43 Outstanding equity awards as of September 30, 202 3 44 Option Exercises and Stock Vested in Fiscal Year 202 3 48 Equity Compensation Plan Information 49 Employment Agreements 49 Potential Payments upon Termination or Change in Control 50 Pay Ratio Disclosure 51 Pay Versus Performance 52

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 56 PROPOSAL 2–NON-BINDING, ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS 59 Vote Required 59 PROPOSAL 3–RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 60 Principal Accountant Fees and Services 61 Pre-Approval Policy 61 Vote Required 61 WHERE YOU CAN FIND MORE INFORMATION 62 FORM 10-K 62 OTHER MATTERS 62 i TABLE OF CONTENTS TWIST BIOSCIENCE CORPORATION 681 Gateway Boulevard South San Francisco, California 94080 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD AT 8:00 AM EASTERN STANDARD TIME ON FEBRUARY 6, 2024 The board of directors (the " Board ") of Twist Bioscience Corporation, a Delaware corporation (the " Company " " Twist ," " we ," " us " and " our "), is soliciting your proxy to vote at the 2024 annual meeting of stockholders (the " Annual Meeting ") of the Company to be held exclusively via live audiocast at www.virtualshareholdermeeting.com/TWST2024 on February 6, 2024, at 8:00 am Eastern Standard Time, including at any adjournment(s) or postponement(s) of the Annual Meeting. You are encouraged to log in to the website above before the Annual Meeting begins. Online check-in will be available approximately 15 minutes before the meeting starts. If you encounter any difficulties accessing or participating in the Annual Meeting through the meeting website, please call the support team at the numbers listed on the website log-in screen. We mailed copies of the proxy materials, which include this proxy statement, a proxy card and our 2023 Annual Report, to stockholders beginning on or about January 5, 2024. You do not need to attend the Annual Meeting via live audiocast to vote your shares. Instead, you may simply vote your shares by proxy via the internet, by telephone or by completing, signing and returning the enclosed proxy card. QUESTIONS AND ANSWERS Why have I received the

View Full Filing

View this DEF 14A filing on SEC EDGAR